世界最先端の研究で医学の発展に寄与

2012年

2012年 業績・論文

Michailidis E, Singh K, Ryan EM, Hachiya A, Ong YT, Kirby KA, Marchand B, Kodama EN, Mitsuya H, Parniak MA, Sarafianos SG.

Effect of translocation defective reverse transcriptase inhibitors on the activity of N348I, a connection subdomain drug resistant HIV-1 reverse transcriptase mutant.

Cell Mol Biol (Noisy-le-grand). 58(1):187-95. 2012.

 

Edwards CK 3rd, Green JS, Volk HD, Schiff M, Kotzin BL, Mitsuya H, Kawaguchi T, Sakata K, Cheronis J, Trollinger D, Bankaitis-Davis D, Dinarello CA, Norris DA, Bevilacqua MP, Fujita M, Burmester GR.

Combined anti-tumor necrosis factor-α therapy and DMARD therapy in rheumatoid arthritis patients reduces inflammatory gene expression in whole blood compared to DMARD therapy alone.

Front Immunol. 3:366. 2012.

 

Kawano Y, Fujiwara S, Wada N, Izaki M, Yuki H, Okuno Y, Iyama K, Yamasaki H, Sakai A, Mitsuya H, Hata H.

Multiple myeloma cells expressing low levels of CD138 have an immature phenotype and reduced sensitivity to lenalidomide.

Int J Oncol. 41(3):876-84. 2012.

 

Sugata K, Satou Y, Yasunaga JI, Hara H, Ohshima K, Utsunomiya A, Mitsuyama M, Matsuoka M.

HTLV-1 bZIP factor impairs cell-mediated immunity by suppressing production of Th1 cytokines.

Blood. 119: 434-44. 2012.

 

Douceron E, Kaidarova Z, Miyazato P, Matsuoka M, Murphy EL, Mahieux R.

HTLV-2 APH-2 expression is correlated with proviral load but APH-2 does not promote lymphocytosis.

J Inf Dis. 205: 82-6. 2012.

 

Okuno Y, Tatetsu H, Nosaka K, Mitsuya H.

Three cases of aggressive natural killer cell leukemia with a lethal hemorrhagic complication.

J Clin Exp Hematop. 52(2):101-6. 2012.

 

Aoki M, Danish ML, Aoki-Ogata H, Amano M, Ide K, Das D, Koh Y, Mitsuya H.

Loss of the protease dimerization inhibition activity of tipranavir (TPV) and its association with the acquisition of resistance to TPV by HIV-1.

J Virol. 86(24):13384-96. 2012.

 

Murphey-Corb M, Rajakumar P, Michael H, Nyaundi J, Didier PJ, Reeve AB, Mitsuya H, Sarafianos SG, Parniak MA.

Response of simian immunodeficiency virus to the novel nucleoside reverse transcriptase inhibitor 4'-ethynyl-2-fluoro-2'-deoxyadenosine in vitro and in vivo.

Antimicrob Agents Chemother. 56(9):4707-12. 2012.

 

Maeda K, Das D, Nakata H, Mitsuya H.

CCR5 inhibitors: emergence, success, and challenges.

Expert Opin Emerg Drugs. 17(2):135-45. 2012.

 

Sohl CD, Kasiviswanathan R, Kim J, Pradere U, Schinazi RF, Copeland WC, Mitsuya H, Baba M, Anderson KS.

Balancing antiviral potency and host toxicity: identifying a nucleotide inhibitor with an optimal kinetic phenotype for HIV-1 reverse transcriptase.

Mol Pharmacol. 82(1):125-33. 2012.

 

Ghosh AK, Chapsal BD, Steffey M, Agniswamy J, Wang YF, Amano M, Weber IT, Mitsuya H.

Substituent effects on P2-cyclopentyltetrahydrofuranyl urethanes: design, synthesis, and X-ray studies of potent HIV-1 protease inhibitors.

Bioorg Med Chem Lett. 22(6):2308-11. 2012.

 

Ghosh AK, Anderson DD, Weber IT, Mitsuya H.

Enhancing protein backbone binding–a fruitful concept for combating drug-resistant HIV.

Angew Chem Int Ed Engl. 51(8):1778-802. 2012.

 

Sohl CD, Singh K, Kasiviswanathan R, Copeland WC, Mitsuya H, Sarafianos SG, Anderson KS.

Mechanism of interaction of human mitochondrial DNA polymerase γ with the novel nucleoside reverse transcriptase inhibitor 4'-ethynyl-2-fluoro-2'-deoxyadenosine indicates a low potential for host toxicity.

Antimicrob Agents Chemother. 56(3):1630-4. 2012.

 

Ndongwe TP, Adedeji AO, Michailidis E, Ong YT, Hachiya A, Marchand B, Ryan EM, Rai DK, Kirby KA, Whatley AS, Burke DH, Johnson M, Ding S, Zheng YM, Liu SL, Kodama E, Delviks-Frankenberry KA, Pathak VK, Mitsuya H, Parniak MA, Singh K, Sarafianos SG.

Biochemical, inhibition and inhibitor resistance studies of xenotropic murine leukemia virus-related virus reverse transcriptase.

Nucleic Acids Res. 40(1):345-59. 2012.

 

Kawano Y, Ueno S, Abe M, Kikukawa Y, Yuki H, Iyama K, Okuno Y, Mitsuya H,

Hata H. TRAIL produced from multiple myeloma cells is associated with osteolytic markers.

Oncol Rep. 27(1):39-44. 2012.

 

Satou Y, Utsunomiya A, Tanabe J, Nakagawa M, Nosaka K, Matsuoka M.

HTLV-1 modulates the frequency and phenotype of FoxP3+CD4+ T cells in HTLV-1 infected individuals.

Retrovirology. 9: 46. 2012.

 

Gazon H, Lemasson I, Polakowski N, Cesaire R, Matsuoka M, Barbeau B, Mesnard JM, Peloponese JM Jr.

Human T-cell leukemia virus type 1 (HTLV-1) bZIP factor requires cellular transcription factor JunD to upregulate HTLV-1 antisense transcription from the 3' long terminal repeat.

J Virol. 86: 9070-8. 2012.

 

Kiyasu J, Aoki R, Tanaka PY, Pracchia LF, Calore EE, Perez NM, Kimura Y, Niino D, Sugita Y, Takayanagi R, Abe Y, Matsuoka M, Ohshima K.

FOXP3(+) regulatory and TIA-1(+) cytotoxic T lymphocytes in HIV-associated Hodgkin lymphoma.

Pathol Int. 62: 77-83, 2012.

 

Mizuhara T, Oishi S, Ohno H, Shimura K, Matsuoka M, Fujii N.

Concise synthesis and anti-HIV activity of pyrimido[1,2-c][1,3]benzothiazin-6-imines and related tricyclic heterocycles.

Org Biomol Chem. 10: 6792-802, 2012.

 

Tanaka G, Nakase I, Fukuda Y, Masuda R, Oishi S, Shimura K, Kawaguchi Y, Takatani-Nakase T, Langel U, Graslund A, Okawa K, Matsuoka M, Fujii N, Hatanaka Y, Futaki S.

CXCR4 stimulates macropinocytosis: implications for cellular uptake of arginine-rich cell-penetrating peptides and HIV.

Chemistry & biology. 19: 1437-1446. 2012.

 

Masuda R, Oishi S, Tanahara N, Ohno H, Hirasawa A, Tsujimoto G, Kodama E, Matsuoka M, Fujii N.

Development and application of fluorescent SDF-1 derivatives.

Future Med Chem. 4: 837-844. 2012.

 

Mizuhara T, Oishi S, Ohno H, Shimura K, Matsuoka M, Fujii N.

Structure-activity relationship study of pyrimido[1,2-c][1,3]benzothiazin-6-imine derivatives for potent anti-HIV agents.

Bioorg Med Chem. 20: 6434-6441. 2012.

 

Li X, Qian H, Miyamoto F, Naito T, Kawaji K, Kajiwara K, Hattori T, Matsuoka M, Watanabe K, Oishi S, Fujii N, Kodama EN.

A simple, rapid, and sensitive system for the evaluation of anti-viral drugs in rats.

Biochem Biophys Res Commun. 424: 257-261. 2012.

お気軽にお問い合わせください TEL 096-373-5156 受付時間 9:00 - 18:00 [ 土・日・祝日除く ]

  • Facebook
  • Hatena
  • twitter
  • Google+
PAGETOP